Difference between revisions of "Team:NTU-Singapore/Demonstrate"

(Replaced content with "{{NTU-Singapore/Nav}} <html> </html>")
Line 1: Line 1:
 
{{NTU-Singapore/Nav}}
 
{{NTU-Singapore/Nav}}
 
<html>
 
<html>
 +
<body>
 +
<!-- Main container -->
 +
<div class="page-container">
 +
   
 +
<!-- bloc-101 -->
 +
<div class="bloc bgc-white bg-T--NTU-Singapore--DNA-Editor d-bloc" id="bloc-101">
 +
<div class="container bloc-xl">
 +
<div class="row">
 +
<div class="col-sm-12">
 +
<h1 class="tc-white  mg-md text-center">
 +
<strong>Demostrate</strong><br>
 +
</h1>
 +
</div>
 +
</div>
 +
</div>
 +
</div>
 +
<!-- bloc-101 END -->
  
 +
<!-- bloc-102 -->
 +
<div class="bloc bgc-white page-title b-parallax none tc-black" id="bloc-102">
 +
<div class="container bloc-md">
 +
<div class="row">
 +
<div class="col-sm-11">
 +
<h2 class="mg-md  tc-black">
 +
<span class="fa fa-chevron-right"></span>&nbsp;RNA Editing in Therapy
 +
</h2>
 +
<p class=" text-left">
 +
One of the key highlights of REPAIR editing is its potential to restore pathogenic mutations back to G from A. Therefore, it is important that this technology can be used to make changes to the mRNA of disease cell lines. As such, we expanded the project to include two cancer cell lines, HeLa (a commonly used cervical cancer cell line) and MCF-7 (a commonly used breast cancer cell line) to investigate the editing efficiency of REPAIR.<br>
 +
</p>
 +
<p class=" text-left">
 +
The genes that we are targeting are KRAS and PPIB, which have already shown promising results in HEK293FT cells. We are particularly interested in KRAS, because KRAS is an oncogene that is closely related to tumor formation. It was found that at least one KRAS mutation is present in up to 25% of all human tumors and it is one of the most frequently activated oncogenes (Beganoyic, 2009). In another study, 33% of KRAS mutations were found to be present in combination with TP53 mutations in 480 tumors examined (Shajani-Yi et. al., 2018). As mutations in KRAS exert such a significant effect in potentially causing cancer, we feel that it is vital that we make use of REPAIR to demostrate to correct the mutations of KRAS.&nbsp;<br>
 +
</p>
 +
<div class="divider-h">
 +
<span class="divider"></span>
 +
</div>
 +
<h2 class="mg-md ">
 +
<span class="fa fa-chevron-right"></span>&nbsp;REPAIR on Cancer Cell-Line
 +
</h2>
 +
<p>
 +
As such, we hope to rea
 +
</p>
 +
</div>
 +
</div>
 +
</div>
 +
</div>
 +
<!-- bloc-102 END -->
 +
 +
<!-- bloc-103 -->
 +
<div class="bloc bgc-white page-title b-parallax none tc-black" id="bloc-103">
 +
<div class="container bloc-md">
 +
<div class="row">
 +
<div class="col-sm-11">
 +
<h2 class="mg-md  tc-black">
 +
<span class="fa fa-chevron-right"></span>&nbsp;Conclusion
 +
</h2>
 +
<p class=" text-left">
 +
In conclusion,<br>
 +
</p>
 +
<h2 class="mg-md ">
 +
<span class="fa fa-chevron-right"></span> References<br>
 +
</h2>
 +
<p>
 +
1.&nbsp;Beganoyic, S. (2009). Clinical significance of the KRAS mutation. Bosnian journal of basic medical sciences, 9(Suppl 1), S17.<br>2.&nbsp;Shajani-Yi, Z., de Abreu, F. B., Peterson, J. D., &amp; Tsongalis, G. J. (2018). Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non–Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing. Neoplasia, 20(3), 256-262.<br>3.&nbsp;<br>
 +
</p>
 +
</div>
 +
</div>
 +
</div>
 +
</div>
 +
<!-- bloc-103 END -->
 +
 +
<!-- ScrollToTop Button -->
 +
<a class="bloc-button btn btn-d scrollToTop" onclick="scrollToTarget('1')"><span class="fa fa-chevron-up"></span></a>
 +
<!-- ScrollToTop Button END-->
 +
 +
 +
</div>
 +
<!-- Main container END -->
 +
   
 +
 +
 +
<!-- Preloader -->
 +
<div id="page-loading-blocs-notifaction"></div>
 +
<!-- Preloader END -->
 +
 +
</body>
 
</html>
 
</html>

Revision as of 21:55, 16 October 2018

Template:Nav

Demostrate

 RNA Editing in Therapy

One of the key highlights of REPAIR editing is its potential to restore pathogenic mutations back to G from A. Therefore, it is important that this technology can be used to make changes to the mRNA of disease cell lines. As such, we expanded the project to include two cancer cell lines, HeLa (a commonly used cervical cancer cell line) and MCF-7 (a commonly used breast cancer cell line) to investigate the editing efficiency of REPAIR.

The genes that we are targeting are KRAS and PPIB, which have already shown promising results in HEK293FT cells. We are particularly interested in KRAS, because KRAS is an oncogene that is closely related to tumor formation. It was found that at least one KRAS mutation is present in up to 25% of all human tumors and it is one of the most frequently activated oncogenes (Beganoyic, 2009). In another study, 33% of KRAS mutations were found to be present in combination with TP53 mutations in 480 tumors examined (Shajani-Yi et. al., 2018). As mutations in KRAS exert such a significant effect in potentially causing cancer, we feel that it is vital that we make use of REPAIR to demostrate to correct the mutations of KRAS. 

 REPAIR on Cancer Cell-Line

As such, we hope to rea

 Conclusion

In conclusion,

References

1. Beganoyic, S. (2009). Clinical significance of the KRAS mutation. Bosnian journal of basic medical sciences, 9(Suppl 1), S17.
2. Shajani-Yi, Z., de Abreu, F. B., Peterson, J. D., & Tsongalis, G. J. (2018). Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non–Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing. Neoplasia, 20(3), 256-262.
3.